The Varying Pharmacology of MDD & BPAD

977 Words2 Pages

While it is diagnostically convenient to group Major Depressive Disorder (MDD) and Bipolar Affective Disorder (BPAD) together, their variance in the recommended pharmacotherapy belies their diagnostic similarities. It is necessary to know the diagnostic features of a depressive episode to diagnose both disorders, and the treatment goal of MDD and BPAD is restoration to euthymic state. The purpose of this paper is to summarize the different medications used with each disorder to achieve that goal. Additionally, this paper will point out the side effects, signs, and symptoms therapists should be aware of during the treatment processes.

Medications Treating MDD

There is a plethora of antidepressants available to treat MDD. Antidepressants vary in the neurotransmitter influenced and the mechanism that produces the effect. For example, Monoamine Oxidase Inhibitors (MAOIs) and Selective Serotonin Reuptake Inhibitors (SSRIs) elevate serotonin levels, but as their respective names suggest do so via different processes. Selection of one of these medications is the first part of the pharmacotherapy process, and it involves understanding prior attempted treatments, family history, number of present symptoms, costs, and medication safety (Kelsey, Newport, & Nemeroff, 2006, pp. 62-63). Once a client begins an antidepressant regimen, therapists should be aware of the selected cautions and side effects. For example, SSRIs offer fewer side effects than MAOIs and Tricyclic Antidepressants (TCAs); however, the initial serotonin increase produced by these drugs may result in increased anxiety symptoms (Kelsey et al., 2006, p. 134). MAOIs operate by inhibiting MAO enzyme metabolization that necessitates dietary restrictions to avoid toxic levels of...

... middle of paper ...

...igher rate than manic episodes (pp. 74-91). Obtaining an extensive biopsychosocial history is necessary in properly identifying and subsequently treating the two disorders. Once treatment begins, therapists must be aware of the hazardous side effects of medications to assist their clients and physicians in treatment of either disorder. It is this author’s hope that the information presented not only helps distinguish the pharmacotherapy of both MDD and BPAD, but also provided cautions to other mental health professionals for side effect monitoring.

Works Cited

Kelsey, J.E., Newport, D. J., & Nemeroff, C.B. (2006). Principles of psychopharmacology for mental health professionals. Hoboken, NJ: John Wiley & Sons, Inc.

Lambert, Kelly & Kinsley, Craig H. (2005). Clinical neuroscience: The neurobiological foundations of mental health. New York, NY: Worth Publishers.

Open Document